Ryan Scott

A colorectal cancer survivor shares what life with an ostomy is really like, offering advice and reassurance for patients adjusting after surgery.

Dr. Matthew Galsky discusses the background of the KEYNOTE-B15 study, the key results and what these findings could mean for patients.

Dr. Christopher Koller discusses rising kidney cancer diagnoses in younger adults, key risk factors and why early detection remains critical.

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit.

An analysis found docetaxel plus ADT to be the most cost-effective therapy for HRR+ metastatic hormone-sensitive prostate cancer.

RAMPART shows early quality-of-life declines with adjuvant Imfinzi and Imjudo, improving over time, though later cognitive and pain effects emerge.

Phase 2 INDIBLADE data support Yervoy and Opdivo before bladder-sparing chemoradiotherapy.

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase 3 genitourinary cancer trials.

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and pain outcomes.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Adding Xofigo to Xtandi extends survival and delays disease progression in men with metastatic castration-resistant prostate cancer with bone involvement.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

The U.S. FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer.

Rodney Haring discusses Indigenous navigation, partnerships and prevention strategies to reduce cancer disparities and improve equity in Native communities

Learn about stage 2 chronic myeloid leukemia, treatment options, side effects, and key questions to guide conversations with your oncologist.

A national report finds cancer workforce shortages and administrative burdens may delay care, with solutions focused on training and efficiency.

Dr. Gwen Nichols explains how Orca‑T may reduce graft-versus-host disease and impact treatment decisions for certain patients with blood cancers.

ACS data show rising five-year survival and shifting cancer care toward survivorship, access to novel therapies and prevention as incidence climbs.

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients live longer after cancer

Dr. McKenzie explains bile duct cancer subtypes, genomic profiling, targeted therapies and multidisciplinary strategies to improve quality of life.

Rising cancer rates in young adults highlight the need for employer support, flexible work and whole-person health programs to improve outcomes.

Dr. McKenzie discusses gallbladder cancer risk factors, imaging signs and how surgery and lymph node evaluation impact outcomes.

Learn diagnosis, treatments, side effects and key questions to help guide shared decisions with your oncology team after stage 4 ccRCC diagnosis.

Charles Walker discusses living liver donation, survivorship challenges and why self-advocacy and awareness are vital for patients with liver cancer

A liver cancer survivor shares transplant insights, dispels living donor myths and urges patients to advocate for informed, hopeful care.

Colleen Mabasa reflected on the importance of self-advocacy, as well as seeking second opinions and ensuring patients understand all available options.

In an interview, liver cancer survivor Charles Walker shared how family support and a living donor transplant changed his treatment journey and outlook.